Solventum Corp. (SOLV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Solventum Corp. stock (SOLV) is currently trading at $64.64. Solventum Corp. PE ratio is 7.21. Solventum Corp. PS ratio (Price-to-Sales) is 1.33. Analyst consensus price target for SOLV is $86.58. WallStSmart rates SOLV as Moderate Buy.
- SOLV PE ratio analysis and historical PE chart
- SOLV PS ratio (Price-to-Sales) history and trend
- SOLV intrinsic value — DCF, Graham Number, EPV models
- SOLV stock price prediction 2025 2026 2027 2028 2029 2030
- SOLV fair value vs current price
- SOLV insider transactions and insider buying
- Is SOLV undervalued or overvalued?
- Solventum Corp. financial analysis — revenue, earnings, cash flow
- SOLV Piotroski F-Score and Altman Z-Score
- SOLV analyst price target and Smart Rating
Solventum Corp.
📊 No data available
Try selecting a different time range
SOLV Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Solventum Corp. (SOLV)
SOLV trades at a significant discount to its Graham intrinsic value of $415.58, offering a 80% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Solventum Corp. (SOLV) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around operating margin and revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Solventum Corp. (SOLV) Key Strengths (7)
Every $100 of shareholder equity generates $39 in profit
Earnings per share surging 100.80% year-over-year
73.67% of shares held by major funds and institutions
Large-cap company with substantial market presence
Good growth relative to its price
Paying $1.33 for every $1 of annual revenue
Strong profitability: $19 kept per $100 revenue
Supporting Valuation Data
Solventum Corp. (SOLV) Areas to Watch (3)
Revenue declining -3.70%, a shrinking business
Very thin margins with limited operational efficiency
Fairly priced relative to book value
Solventum Corp. (SOLV) Detailed Analysis Report
Overall Assessment
This company scores 70/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 7 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 2.7/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Return on Equity, EPS Growth, Institutional Own.. Valuation metrics including PEG Ratio (1.22), Price/Sales (1.33) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 38.90%, Profit Margin at 18.70%. Growth metrics are encouraging with EPS Growth at 100.80%.
The Bear Case
The primary concerns are Revenue Growth, Operating Margin, Price/Book. Some valuation metrics including Price/Book (2.26) suggest expensive pricing. Growth concerns include Revenue Growth at -3.70%, which may limit upside. Profitability pressure is visible in Operating Margin at 7.01%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 38.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -3.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and EPS Growth makes a compelling case at current levels. The key risk is Revenue Growth, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B- grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SOLV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SOLV's Price-to-Sales ratio of 1.33x sits near its historical average of 1.47x (10th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 25% below its historical high of 1.79x set in Nov 2025, and 19% above its historical low of 1.12x in Jun 2024. Over the past 12 months, the PS ratio has compressed from ~1.6x as trailing revenue scaled faster than the stock price.
Compare SOLV with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Solventum Corp. (SOLV) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Solventum Corp. faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 8.3B with 4% decline year-over-year. Profit margins of 18.7% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 38.9% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 32M in free cash flow and 95M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Debt management: total debt of 5.1B is significantly higher than cash (1.6B). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Solventum Corp..
Bottom Line
Solventum Corp. faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 12:57:00 PM
About Solventum Corp.(SOLV)
NYSE
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.